Stock VTGN VISTAGEN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

MarketScreener Editorial Features Vistagen Therapeutics, Inc.

Equities

VTGN

US92840H4002

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
4.75 USD +1.06% Intraday chart for Vistagen Therapeutics, Inc. -0.21% -7.59%
Apr. 25 Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue CI
Apr. 01 Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 CI

MarketScreener Editorial Features

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Global markets live: Rio Tinto, Bank of America, J&J, Pfizer, Microsoft...Global markets live: Rio Tinto, Bank of America, J&J, Pfizer, Microsoft... October 17, 2023 at 11:50 am EDT
Rate hike fears return with a vengeanceRate hike fears return with a vengeance October 17, 2023 at 09:20 am EDT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VTGN Stock
  4. News Vistagen Therapeutics, Inc.
  5. MarketScreener Editorial Features